Kite Pharma Announces Proposed Public Offering of Common Stock
December 08, 2015 16:01 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has commenced an underwritten public offering of approximately $250 million of shares of...
Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)
December 07, 2015 12:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor (CAR)...
Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting
December 07, 2015 10:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced clinical results and biomarker data for the phase 1 portion of Kite's ZUMA-1 trial of KTE-C19 in...
Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
December 07, 2015 06:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...
Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults
December 07, 2015 06:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-4) for the treatment of...
Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
December 03, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif. and NISKAYUNA, N.Y., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T...
Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects
December 02, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy...
Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update
November 12, 2015 16:01 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Host Third Quarter 2015 Financial Results Conference Call and Webcast
November 09, 2015 16:01 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that management will host a conference call and live webcast discussion at 4:30 p.m. Eastern Time...
Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication
November 09, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...